Collectively, these studies demonstrate that IL-8-driven cancer stemness appears to be a common mechanism that is conserved across multiple tumor types, and, importantly, that this mechanism is amenable to therapeutic intervention via CXCR1/2 inhibition. This evidence concerns the gene CXCL8 and cancer.